Skip to main content
. 2017 Aug 11;8(46):80560–80567. doi: 10.18632/oncotarget.20156

Figure 2. TIMP-2 in lung cancer patients and benign diseases.

Figure 2

(A) Comparison of TIMP-2 levels in BALF between lung cancer and control group. The levels of TIMP-2 were significantly higher in lung cancer patients than those in controls (*P < 0.05). (B) Representative examples of immunohistochemistry of TIMP-2 expression in human lung specimens. (C) Quantification of TIMP-2 expression in the lung cancer and benign diseases (**P < 0.01). (D) In subgroup analysis by tumor histology, BALF MMP-2 in different cell types of lung cancer patient. (E) BALF TIMP-2 concentration were assessed according to TNM stage. Values in the box plot are given as median (interquartile range); BALF, bronchoalveolar lavage fluid; SCC, squamous cell carcinoma; ADC, adenocarcinoma; SCLC, small-cell lung cancer.